IDH2 and central nervous system cancer: Indeed, most (>70%) diffuse grade II gliomas carry a recurrent missense mutation in the IDH1 or IDH2 (isocitrate dehydrogenase 1/2) genes, with IDH1R132H being the most commonly identified mutation (90%) [5,6,7,8].